Pharma Partnerships Ribometrix has a history of pharma collaboration, including Roche, and a January 2025 leadership refresh signaling readiness for expanded strategic deals. The platform targets functional 3D RNA structures with small molecules, a niche area pharma is actively exploring for novel modalities. Key sales opportunities include pursuing co-development or exclusive licensing deals with mid-to-large pharma focused on oncology, genetic diseases, and rare conditions, as well as offering discovery and optimization services to de-risk early collaborations.

Regional Growth With offices in Durham, Chapel Hill, and Boston and renovated space in Biolabs, Ribometrix is well positioned to engage universities, biotech startups, and CROs across major biotech clusters. This enables sponsored research programs, pilot collaborations, and early-stage discovery partnerships that generate milestone-driven revenue, while also providing access to regional talent and potential co-development opportunities.

Platform Capabilities The company’s capabilities in RNA structure targeting, supported by Illumina sequencing, AWS, and related tools, offer a full-stack discovery engine for RNA-targeted small molecules. This creates selling points for customers seeking end-to-end services, including structure-guided lead discovery, data analytics, and preclinical candidate identification, as well as potential collaboration on assay development or companion diagnostics.

Financial Readiness With revenue in the low-to-mid single digits and total funding under eight million, Ribometrix presents a lean, milestone-driven partnership model. Sales opportunities include structuring non-dilutive funding options, sponsored research programs, and milestone-based collaborations that align with pharma budgets and risk tolerance, complemented by potential grants or university partnerships to de-risk early-stage work.

Leadership Focus The January 2025 leadership changes create an inflection point for business development strategy. Engage executive-level discussions to map platform capabilities to priority therapeutic areas and target product profiles, leveraging the Roche collaboration as a proof point and pursuing updated co-development or licensing opportunities with top pharma players aligned to the new leadership’s priorities.